OncoSec Medical Inc (ONCSQ)

[hschlauch]

The actual pembrolizumab non-responders in ONCS's phase 2 metastatic melanoma trial - 83% of them if my memory serves me correct - had baseline CTLA-4hi/PD-1hi TIL levels below 5%. Those are very low percentages, so to get the phenotype percentages over 20% would be quite amazing.

By the way, for the exploratory and validation pembrolizumab monotherapy cohorts examined by UCSF in their biomarker study, only 17% were under that 5% phenotype level! So to have 83% of your pembrolizumab non-responders under 5% is quite anamolous if the exploratory and validation cohorts in the biomarker study are representive of the non-responder population.